Kedrion supports World Primary Immunodeficiency Week

Always close to those who live with rare diseases, Kedrion Biopharma is proud to support World Primary Immunodeficiency Week (PI WEEK 2021), scheduled for April 22 – 29. This is a global campaign aimed at promoting and protecting the health of patients with Primary Immunodeficiencies (PI) by improving – first and foremost – early diagnosis and prompt access to treatment.

Educational initiatives, awareness activities and medical-scientific round tables will be held throughout the week, for the second consecutive year in virtual mode, promoted by patient associations, academia, companies and institutions around the world. The main topics of these meetings include: the importance of plasma availability to ensure that people with PID receive the treatment they need; the safety and protection of patients, focusing particularly on the key role of vaccination to protect the most vulnerable people during this pandemic; enhance the quality of life of patients through research, early diagnosis and improved access to treatment.In line with this perspective aimed at safeguarding and improving the quality of life of patients, Kedrion has continued its commitment to this therapeutic area over the past year, as confirmed/testified by the enrollment – on March 31, 2021 – of the first patient in a phase 3 clinical study geared towards demonstrating the efficacy, safety and pharmacokinetics of a 10% Intravenous Immunoglobulin (IVIg) in pediatric patients with IDP.

Even during the most difficult moments of this pandemic, , we have continued to collaborate in the same spirit with the International Patients Organization for Primary Immunodeficiencies (IPOPI) by confirming our support to PID GENIUS; the first app designed and developed by IDP patients with the technical and economic support of our company. At the same time, we have backed a number of initiatives organized by patient associations in various countries around the world, including for example the United States, , where we have renewed our support to the American Immunodeficiency Foundation (IDF) and the Jeffrey Modell Foundation.